Norebox (Reboxetine)

Reboxetine, the active ingredient in Norebox, is a selective norepinephrine reuptake inhibitor presented as an oral tablet (strength not specified) for oral use. It is indicated for the treatment of major depressive disorder in adult patients. GNH USA supplies Norebox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Reboxetine acts on the norepinephrinergic pathway and is employed in the management of depressive disorders. - Major depressive disorder: reduces depressive symptoms and improves functional outcomes in adults. - Treatment‑resistant depression (off‑label): may be considered when first‑line agents are ineffective, under specialist supervision. - Adjunctive therapy for chronic pain (off‑label): can provide modest analgesic benefit by enhancing norepinephrine levels.

Reboxetine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dry mouth: reduced salivation leading to discomfort. - Insomnia: difficulty initiating or maintaining sleep. - Constipation: decreased bowel motility. - Dizziness: transient light‑headedness. - Sweating: increased perspiration.

Serious or Rare Side Effects: - Elevated blood pressure: hypertension requiring monitoring. - Suicidal thoughts: emergence of suicidal ideation, especially early in therapy. - Severe liver injury: rare hepatotoxicity with jaundice. - Cardiac arrhythmia: abnormal heart rhythms in susceptible individuals. - Anaphylaxis: acute allergic reaction with rash, swelling, or breathing difficulty.

Before initiating Reboxetine, clinicians should evaluate several safety considerations. - Blood pressure monitoring: check baseline and periodic readings. - Suicidality assessment: screen for suicidal thoughts, particularly in the first weeks. - Hepatic function: use caution in patients with liver impairment. - Discontinuation: avoid abrupt cessation to reduce withdrawal symptoms. - Drug interactions: review concomitant serotonergic or sympathomimetic agents. - Store at ambient temperature: keep in the original pack, protect from moisture.

Reboxetine can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors: risk of hypertensive crisis. - Selective serotonin reuptake inhibitors: potential serotonin syndrome. - Tricyclic antidepressants: additive cardiovascular effects. - Strong CYP2D6 inhibitors: increased reboxetine plasma levels. - Sympathomimetic agents: excessive adrenergic stimulation.

Moderate Interactions (Monitor Closely):\n- Antihypertensive drugs: possible attenuation of blood‑pressure‑lowering effect. - Non‑steroidal anti‑inflammatory drugs: heightened risk of gastrointestinal bleeding. - Anticholinergic medications: amplified dry‑mouth and constipation. - Alcohol: may worsen sedation and dizziness. - CYP2D6 substrates: monitor for altered metabolism of co‑administered drugs.